Results 1 to 10 of about 692,269 (276)

TWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitors. [PDF]

J Exp Clin Cancer Res
Abstract Background Tumors that retain wild-type TP53 and rely on MDM2 overexpression to dampen the p53 response were considered prime candidates for therapies based on MDM2 inhibitors (MDM2i).
Piccinin S, Szaboova B, Pivetta F, Del Savio E, Belli E, Gloazzo S, Doriguzzi Breatta E, Baldazzi D, Rosano C, Sigalotti L, Maestro R.   +10 more
europepmc   +2 more sources

Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. [PDF]

Blood Adv, 2022
Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang M, Fang B.   +23 more
europepmc   +1 more source

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. [PDF]

Hemasphere, 2022
Hohtari H, Kankainen M, Adnan-Awad S, Yadav B, Potdar S, Ianevski A, Dufva O, Heckman C, Sexl V, Kytölä S, Mustjoki S, Porkka K.   +11 more
europepmc   +1 more source

Ligand-Based and Docking-Based Virtual Screening of MDM2 Inhibitors as Potent Anticancer Agents. [PDF]

Comput Math Methods Med, 2021
Li BH, Ge JQ, Wang YL, Wang LJ, Zhang Q, Bian C.   +5 more
europepmc   +1 more source

Computational identification of potential natural terpenoid inhibitors of MDM2 for breast cancer therapy: molecular docking, molecular dynamics simulation, and ADMET analysis

Frontiers in Chemistry
BackgroundBreast cancer (BC) remains a leading cause of cancer-related mortality in women. The oncoprotein MDM2 negatively regulates the tumor suppressor p53, and its overexpression in BC promotes tumor progression and resistance to therapy.
Eva Azme, Md. Mahmudul Hasan, Md. Liakot Ali, Rashedul Alam, Rashedul Alam, Neamul Hoque, Fabiha Noushin, Mohammed Fazlul Kabir, Ashraful Islam, Tanzina Sharmin Nipun, S. M. Moazzem Hossen, Hea-Jong Chung, Hea-Jong Chung   +12 more
doaj   +1 more source

Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation. [PDF]

Front Chem, 2021
Aziz YMA, Lotfy G, Said MM, El Ashry ESH, El Tamany ESH, Soliman SM, Abu-Serie MM, Teleb M, Yousuf S, Dömling A, Domingo LR, Barakat A.   +11 more
europepmc   +1 more source

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms. [PDF]

Leukemia
Al-Ali HK, Heidel ST, Palandri F, Heidel FH.   +3 more
europepmc   +1 more source

Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. [PDF]

Cancer Res Commun
Liu CT, Su YY, Chiang NJ, Li CF, Ma YC, Chang KC, Hung YH, Hung WC, Chen LT.   +8 more
europepmc   +1 more source

Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer. [PDF]

NPJ Precis Oncol
Vargas R, Petty A, Lindner DJ, Parker Y, Yard B, Durmaz A, Lin-Rahardja K, Reizes O, Debernardo R, Scott J.   +9 more
europepmc   +1 more source

Selective Cleaning Enhances Machine Learning Accuracy for Drug Repurposing: Multiscale Discovery of MDM2 Inhibitors. [PDF]

Molecules
Akmal MF, Wong MW.
europepmc   +1 more source